Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

被引：17
|
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Mikhailidis, Dimitri P. [2 ]
Mantzoros, Christos [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] UCL, Royal Free Hosp Campus, Med Sch, Dept Clin Biochem, London, England
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2017年 / 74卷
关键词：
GENETIC-VARIANTS; REDUCING LIPIDS; STATIN THERAPY; MANAGEMENT; EVOLOCUMAB; EFFICACY; SAFETY; DYSLIPIDEMIA; ASSOCIATION; ALIROCUMAB;
D O I：
10.1016/j.metabol.2017.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 46
页数：4
相关论文
共 50 条
  • [31] The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells
    Ben Zadok, O. Itzhaki
    Mager, A.
    Leshem-Lev, D.
    Lev, E.
    Kornowski, R.
    Eisen, A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1828 - 1828
  • [32] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Sun, Huimin
    Meng, Wen
    Zhu, Jie
    Wang, Lu
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (06) : 643 - 658
  • [33] Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
    Milionis, Haralampos
    Barkas, Fotios
    Ntaios, George
    Papavasileiou, Vasileios
    Vemmos, Kostantinos
    Michel, Patrick
    Elisaf, Moses
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 34 : 54 - 57
  • [34] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Huimin Sun
    Wen Meng
    Jie Zhu
    Lu Wang
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395 : 643 - 658
  • [35] Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
    Schreckenberg, Rolf
    Wolf, Annemarie
    Szabados, Tamara
    Gomori, Kamilla
    Szabo, Istvan Adorjan
    Agoston, Gergely
    Brenner, Gabor
    Bencsik, Peter
    Ferdinandy, Peter
    Schulz, Rainer
    Schlueter, Klaus-Dieter
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (12)
  • [36] The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
    Parikh, Riya R.
    Breve, Frank
    Magnusson, Peter
    Behzadi, Payam
    Pergolizzi, Joseph
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [37] Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects
    Wan, Hong
    Gumbiner, Barry
    Joh, Tenshang
    Riel, Tom
    Udata, Chandrasekhar
    Forgues, Philippe
    Garzone, Pamela D.
    CLINICAL THERAPEUTICS, 2017, 39 (11) : 2243 - 2259
  • [38] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease
    Alkhalil, Mohammad
    CURRENT DRUG METABOLISM, 2019, 20 (01) : 72 - 82
  • [39] Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
    Seidah, Nabil G.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (17) : 3161 - 3172
  • [40] Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors: a district general hospitals experience
    Whicher, C. A.
    Tjerkstra, E.
    Waise, A.
    DIABETIC MEDICINE, 2017, 34 : 155 - 155
12345